S&P 500Health Care· USA

BIIB

Challenger

Biogen

$176.37

+1.98%

Open $172.62·Prev $172.94

as of 13 Apr

CHALLENGER

Power Core

Biogen's moat is its deep institutional expertise in neuroscience drug development, spanning biology, clinical trial design, and regulatory navigation in CNS disorders, a domain where most competitors fail.

Published1 Apr 2026

UniverseS&P 500

SectorHealth Care

↑

Direction of Movement

Lateral Transition With Upward Optionality If Execution Delivers

ROC 200

+35.3%

Referenced in 19 other analyses

Financials